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Abstract
Neurodegenerative disorders such as Parkinson’s Disease (PD), PD dementia (PDD) and Dementia with Lewy
bodies (DLB) are characterized by progressive accumulation of α-synuclein (α-syn) in neurons. Recent studies have
proposed that neuron-to-neuron propagation of α-syn plays a role in the pathogenesis of these disorders. We have
previously shown that antibodies against the C-terminus of α-syn reduce the intra-neuronal accumulation of α-syn
and related deficits in transgenic models of synucleinopathy, probably by abrogating the axonal transport and
accumulation of α-syn in in vivo models. Here, we assessed the effect of passive immunization against α-syn in a
new mouse model of axonal transport and accumulation of α-syn. For these purpose, non-transgenic, α-syn
knock-out and mThy1-α-syn tg (line 61) mice received unilateral intra-cerebral injections with a lentiviral (LV)-α-syn
vector construct followed by systemic administration of the monoclonal antibody 1H7 (recognizes amino acids 91-99)
or control IgG for 3 months. Cerebral α-syn accumulation and axonopathy was assessed by immunohistochemistry and
effects on behavior were assessed by Morris water maze. Unilateral LV-α-syn injection resulted in axonal propagation of
α-syn in the contra-lateral site with subsequent behavioral deficits and axonal degeneration. Passive immunization with
1H7 antibody reduced the axonal accumulation of α-syn in the contra-lateral side and ameliorated the behavioral
deficits. Together this study supports the notion that immunotherapy might improve the deficits in models of
synucleinopathy by reducing the axonal propagation and accumulation of α-syn. This represents a potential new
mode of action through which α-syn immunization might work.
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Introduction
Synucleinopathies affect over 1 million people in the
US alone [49]. This heterogeneous group of disorders
includes idiopathic Parkinson’s disease (PD), PD de-
mentia (PDD) and dementia with Lewy bodies (DLB)
[48]. Synucleinopathies are clinically characterized by cog-
nitive decline, behavioral alterations with hallucinations
and depression, REM sleep behavior disorder, olfactory
deficits, bowel movement alterations and dysautonomia
[59]. The definitive diagnosis of synucleinopathies is made
pathologically by the detection of Lewy bodies and neur-
ites, which are composed mainly of α-synuclein (α-syn)
and are found in neocortical, limbic and subcortical
regions as well as in peripheral organs. In synucleinopa-
thies, α-syn accumulates in synaptic terminals [5, 28,
58] axons [15, 18] and the neuronal cell body cytoplasm
[61]. In these sites, α-syn accumulates as aggregated
species (oligomers, protofibrils and fibrils) [9, 21, 25,
29, 30, 51, 63, 67, 68, 73]. Aggregated α-syn species are
believed to cause neurodegeneration and to be
* Correspondence: rrissman@ucsd.edu
ˆDeceased
1Departments of Neurosciences, University of California, La Jolla, San Diego,
CA 92093, USA
4Veterans Affairs San Diego Healthcare System, San Diego, CA 92161, USA
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Spencer et al. Acta Neuropathologica Communications  (2017) 5:7 
DOI 10.1186/s40478-016-0410-8
transmitted from neuron to neuron via a prion-like
propagation [32, 53].
Various neuropathological studies suggest that the
spatial and temporal patterns of distribution of α-syn
pathology in the CNS among the different types of
synucleinopathies follow known patterns of synaptic
connectivity [6, 14, 65]. This, in combination with
recent studies showing that α-syn oligomers can be re-
leased by neurons and promote neurodegeneration and
inflammation by propagating to other neurons [8, 12,
20, 37, 50] and glial cells [35], has strengthened the
concept that cell-to-cell transmission of pathogenic
forms of α-syn might play a role in the pathogenesis of
synucleinopathies. Several mechanisms have been pro-
posed to explain the cell-to-cell transmission of α-syn
including prion-like seeding mediated by fibrils [37, 52,
53], release into the Interstitial fluid [27] or in micro-
vesicles containing α-syn aggregates [10, 15, 26, 36],
transmission via nanotubules [69] and trans-synaptic
dissemination [7, 11, 22, 62]. Supporting the later hy-
pothesis, recent studies have shown that injections of
α-syn with viral vectors into the nucleus of vagus [22]
or fibrils into the olfactory bulb [38, 47, 55, 56], stri-
atum or limbic system [38] results in α-syn distribution
along axons and synapses following known patterns of
synaptic connectivity.
We have previously shown that active immunization
against α-syn protects against neurodegeneration and re-
duces α-syn accumulation by promoting its degradation
via lysosomal pathways [43] and reduces inflammation
via fractalkine [39]. Likewise, passive immunization with
antibodies against α-syn reduces memory and neurode-
generative deficits by promoting clearance of α-syn via
autophagy [44] or microglia-dependent degradation [3].
Furthermore, immunization to certain epitopes of α-syn
might also reduce α-syn propagation to glial and neur-
onal cells [3, 72], by blocking the C-terminal (CT) trun-
cation of α-syn [19, 72] and prion-like propagation
[66]. Moreover, we have recently shown that monoclo-
nal antibodies against the proximal (1H7, aa 91-99) or
distal C-terminus of α-syn (9E4 or 5C1, aa 118-126) re-
duced the cell-to-cell propagation of α-syn in an in
vitro chamber system where acceptor and donor cells
were separated by a membrane [19]. However, it is un-
clear if immunization might also abrogate the axonal
transport and accumulation of α-syn in in vivo models
of synucleinopathy. Therefore, we directly explored the
effect of passive immunization against α-syn with the
1H7 antibody in a new mouse model of axonal trans-
port and accumulation of α-syn. To model the axonal
transport and accumulation of α-syn in vivo, a lenti-
virus containing the human α-syn was unilaterally de-
livered in the hippocampus by stereotaxic injection and
α-syn protein was monitored on the ipsilateral and
contra-lateral side, the later in both axonal projections
(commissural fibers) and intraneuronal (neuronal trans-
mission). The 1H7 monoclonal was selected because
this antibody recognizes aggregated α-syn, reduces α-
syn accumulation in the mThy1-α-syn transgenic (tg)
mouse and has been shown to reduce the propagation
in an in vitro cell based model [19]. Non-transgenic
(non-tg), α-syn knock-out (KO) and mThy1-α-syn tg
(line 61) mice received intra-cerebral injections with a
lentiviral (LV)-human-α-syn vector construct followed
by systemic administration of the monoclonal antibody
1H7 or isotype control IgG for 3 months. Passive
immunization with 1H7 antibody reduced α-syn axonal
transport and accumulation in the contra-lateral side
and axonal degeneration and ameliorated the behav-
ioral deficits, further supporting the notion that
immunization against α-syn might be of therapeutic
value for synucleinopathies.
Materials and methods
Mouse model of α-syn axonal transmission to the
contralateral side and passive immunization
In this study we used groups of 3-4 month old female
non-tg mouse littermates, homozygous α-syn KO and
mice over-expressing human wt α-syn under the mThy1
promoter (mThy1-α-syn, Line 61) [57]. The wtα-syn tg
mouse model was selected because these mice develop
behavioral motor deficits [16], axonal pathology and accu-
mulation of CT-cleaved α-syn and aggregates in cortical
and subcortical regions [18] mimicking synucleinopathies
[46]. The α-syn KO mice were obtained from Jackson
laboratories (ID:003692, Maine, USA; B6;129X1-
Sncatm1Rosl/J) these mice were generated by replacing
exons 3-7 with a PGK-neo cassette [1].
To characterize the model, groups of non-tg, α-syn-
KO and α-syn tg mice received a single unilateral injec-
tions into the hippocampus of either LV-control (empty
vector) or the LV-human-α-syn [4] (n = 10 per group)
(2 μl at titer 2 x 109 TDU). Mice were sacrificed for ana-
lysis 4 weeks after the injection. Lentivirus vectors were
prepared by transient transfection of the three packaging
plasmids and the vector plasmid in 293 T cells as previ-
ously described [60, 64]. Briefly, as previously described
[40], mice were placed under anesthesia on a Koft
stereotaxic apparatus and coordinates (hippocampus: AP
2.0 mm, lateral 1.5 mm, depth 1.3 mm) were determined
as per the Franklin and Paxinos atlas [17]. The lentiviral
vectors were delivered using a Hamilton syringe con-
nected to a hydraulic system to inject the solution at a
rate of 1 μl every 2 min. To allow diffusion of the solu-
tion into the brain tissue, the needle was left for an
additional 5 min after the completion of the injection.
Upon sacrifice, the brain was removed. In a subset of
mice (n = 5 per group) the brains were post-fixed in
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phosphate-buffered 4% paraformaldehyde (pH 7.4) at
4 °C for 48 h for neuropathological analysis, while in
the other subset (n = 5 per group) the brains were di-
vided along the sagittal plane, snap-frozen, and stored
at -70 °C for subsequent DNA analysis.
For the immunotherapy experiments, 19 non-tg, 17 α-
syn KO and 16 α-syn tg mice were included in this ran-
domized and double-blind study. Starting the day after
lentivirus (LV) injection, mice were immunized with
weekly intraperitoneal injections of 30 mg/kg of 1H7
(anti–α-syn 91-99) or 27-1 (control immunoglobulin G1
[IgG1]) for a period of 3 months (Fig. 1a). The 1H7
monoclonal antibody was generated with recombinant
α-syn and has been shown to recognize with high affin-
ity aggregated α-syn, to reduce α-syn accumulation, to
protect against behavior deficits in the mThy1-α-syn tg
and to block propagation in an in vitro cell based model
[19]. Each cohort of non-tg, α-syn KO and α-syn tg mice
received either the 1H7 antibody or the control mAb
27-1 as follows: α-Syn KO mice + 27-1 (control) n = 8;
α-syn KO + 1H7 antibody n = 9; non-tg mice + 27-1
(control) n = 10; non-tg mice + 1H7 antibody n = 9; α-
syn tg mice + 27-1 (control) n = 8; α-syn tg mice + 1H7
antibody n = 8. As a control, an additional group of n = 9
non-tg mice were injected with LV-control and treated
with 27-1. To verify that the antibody permeated into the
CNS, a subset of n = 6 α-Syn KO; n = 6 non-tg and n = 6
α-syn tg mice were injected in the tail vein with Alexa
tagged 27-1 control mAb (n = 3 per group; 10 mg/kg) or
1H7 antibody (n = 3 per group; 10 mg/kg) prepared as
previously described [44].
Behavioral tests were performed at the end of the
immunization protocol. Upon sacrifice, the whole brain
was removed and post-fixed in phosphate-buffered 4%
paraformaldehyde (pH 7.4) at 4 °C for 48 h for neuro-
pathological analysis. All experiments were approved by
the institutional animal use and care committee of the
UC San Diego (UCSD) and were performed according to
NIH guidelines for animal use.
Behavioral testing
In patients with synucleinopathies, α-syn accumulates in
cortical regions and the limbic system resulting in cogni-
tive deficits [13]. In the mThy1-α-syn tg mice, CT-
truncated and oligomeric α-syn accumulates in synapses
and axons in the temporal cortex and hippocampus [18].
To evaluate spatial learning and memory, the Morris
water maze was used as previously described [44].
Briefly, a pool (diameter 180 cm) was filled with opaque
water (24 °C) and mice were first trained to locate a vis-
ible platform (days 1-3) and then a submerged hidden
platform (days 4-7) in three daily trials, 2-3 min apart.
Mice that failed to find the hidden platform within 90 s
were placed on it for 30 s. The same platform location
was used for all sessions and all mice. The starting point
at which each mouse was placed into the water was
changed randomly between two alternative entry points
located at a similar distance from the platform. In
addition, on the final day of testing, the platform was re-
moved and the time spent by mice in the correct quad-
rant was measured (probe test). Time to reach the
platform (escape latency) was recorded with a Noldus
Fig. 1 Schematic overview of the experimental paradigm. a Study Design. α-Syn KO, non-tg, and α-syn tg mice were injected with LV-α-syn
1 week before beginning passive immunization with systemic (intraperitoneal) injections of either control IgG (27-1) or α-syn 91-99 antibody
(1H7). Immunization occurred once a week for a total of 13 weeks. Water maze testing occurred 14 weeks after LV-α-syn injection. Mice were
euthanized 16 weeks after LV-α-syn injection. b Schematic representation of the unilateral injection of LV-α-syn into the hippocampus. c Schematic
representation of the α-syn molecule and the binding epitope of the 1H7 antibody. Area in red represents the central hydrophobic region [23, 24, 70]
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Instruments EthoVision video tracking system (San
Diego Instruments, San Diego, CA), set to analyze two
samples per second.
PCR analysis of lentivirus expression
In addition to the cohort of mice used for behavior,
DNA was extracted from the hippocampus, both ipsi-
and contralateral to the site of the lentiviral injection
with either LV-α-syn or LV-GFP, from a separate cohort
of non-tg, α-syn KO and α-syn tg mice (n = 5), and PCR
was performed to analyze the levels of virus. Total DNA
was isolated from mice brains with the DNeasy Blood &
Tissue kit (Qiagen). Real-time PCR analysis was per-
formed using the StepOnePlus real-time PCR system
(Applied Biosystems) with primers specific for the virus
human α-syn (5’-TGT TGG AGG AGC AGT GGT GA-
3’ and 5’-TGC CCA ACT GGT CCT TTT TG-3’) or
GFP (5'- GGA GCG CAC GAT CTT CTT CA-3' and 5'-
AGG GTG TCG CCC TCG AA-3’). Viral presence was
calculated by the comparative threshold cycle (Ct)
method using a standard curve of purified LV-α-syn and
analysis of GADPH was performed as internal control.
Immunohistochemical and neuropathological analysis
Analysis of α-syn accumulation was performed using
free-floating coronal brain sections (40 μm). Brain sec-
tions were incubated overnight at 4 °C with a polyclonal
antibody against total α-syn (1:500, affinity-purified
rabbit polyclonal, Millipore) [45], an antibody against
CT-truncated α-syn (SYN105) [18], or isotype controls
(background levels), followed by incubations with sec-
ondary antibodies biotinylated (1:100, Vector Laborator-
ies, Inc., Burlingame, CA), Avidin D-HRP (1:200, ABC
Elite, Vector) and detection with 3,3’-diaminobenzidine
[44]. All sections were processed simultaneously under
the same conditions and experiments were performed in
triplicate in order to assess the reproducibility of results.
Sections were analyzed with an Olympus BX41 digital
video microscope equipped with a Optronics magna
fire SP camera, LucisTM DHP unique contrast en-
hancement software and Image Pro ExpressTM for live
image acquisition and processing at 630X magnifica-
tion. For each section 4 areas of interest (1024 x
1024 pixels) within the hippocampal neuropil, CA1
region and axons above the hippocampus in the area
ipsilateral and contralateral were analyzed in real time
using the Image Pro Plus (Media Cybernetics) software.
α-Syn levels of immunoreactivity in the hippocampus
neuropil and in axons in the white matter tracts were
expressed as corrected optical density (arbitrary units).
Analysis was performed around the area of injection
within a 50 μm ratio.
Double immunolabeling and confocal microscopy
To evaluate the effects of immunization on the LV-α-syn
driven axonal pathology and propagation, sections were
immunolabeled with an antibody against the neurofila-
ment marker SMI312 (1:100) [42, 60]. In addition,
sections were double-immunolabeled with the CT-
truncated-α-syn antibody SYN105 (1:500) [18] and the
anti-human α-syn antibody SYN211 (Millipore). α-Syn
propagation in the dystrophic axons was detected with
the Tyramide Signal Amplification™-Direct (Red) system
(1:100, NEN Life Sciences, Boston, MA), while the
SYN211 was detected with a FITC-tagged antibody
(Vector, 1:75). To evaluate the clearance of α-syn by
microglia, briefly as previously described [33, 34] sec-
tions were double labeled with antibodies against α-syn
(Millipore, 1:500) detected with Tyramide Signal Amp-
lification™-Direct (Red) system and Iba-1 (a microglial
marker, 1:2500, Wako) detected with FITC. All sections
were processed simultaneously under the same condi-
tions and experiments were performed in triplicate in
order to assess the reproducibility of results. Sections
were imaged with a Zeiss 63X (N.A. 1.4) objective on
an Axiovert 35 microscope (Zeiss) with an attached
MRC1024 LSCM (laser scanning confocal microscope)
system (BioRad) [45]. Image analysis using Image J was
utilized as previously described [41] to determine the
percent of microglia displaying α-syn immunoreactivity.
Statistical analysis
All experiments were done blind-coded and in triplicate.
Values in the figures are expressed as means ± SEM. To
determine the statistical significance, values were com-
pared using Student’s t-test, one-way analysis of variance
(ANOVA) with Dunnett’s post-hoc test or Tukey-
Kramer post-hoc test, as indicated in each figure legend.
The differences were considered significant if p values
were less than 0.05.
Results
α-Syn transmits and accumulates in axons in the
contralateral side following unilateral LV-α-syn injection
into the hippocampus
To evaluate if antibodies against α-syn can reduce
axonal transport and accumulation of α-syn in the
contralateral side, we first developed a new animal
model of neuronal α-syn transmission utilizing unilateral
intra-hippocampal injections of LV-control or LV-α-syn
into α-syn-KO, non-tg and α-syn tg mice (Fig. 1). Four
weeks post LV-α-syn injection, brains were fixed and
sectioned in the coronal plane and analyzed histologi-
cally. As expected, the α-syn-KO mice (Fig. 2a, b) did
not show α-syn immunoreactivity, while non-tg mice
(Fig. 2c, d), and α-syn tg mice (Fig. 2e, f ) injected with
the LV-control (empty vector) only showed punctate α-
Spencer et al. Acta Neuropathologica Communications  (2017) 5:7 Page 4 of 15
syn immunoreactivity restricted mostly to synaptic sites
in both the ipsilateral or contralateral sides. In contrast,
the α-syn KO mice injected with LV-α-syn showed in-
tense α-syn immunoreactivity throughout the hippocam-
pus in the ipsilateral site, including neuronal cell bodies
and neuropil (Fig. 2g, h – right panels). The trans-
hippocampal axons (commissural fibers) and corpus
callosum axons also displayed α-syn immunoreactivity.
In the contralateral hippocampi, somatic α-syn immuno-
reactivity was detected in the molecular layer of the den-
tate gyrus and subiculum as well as in axons in the
subiculum and corpus callosum (Fig. 2g, h – left panels).
The contralateral side displayed somatic α-syn aggre-
gates ranging in size between 3-6 μm in diameter
Fig. 2 Immunohistochemical analysis of LV-αsyn in α-syn KO, non-tg, and α-syn tg mice. α-syn KO, non-tg and α-syn tg mice were evaluated
16 weeks after unilateral LV injection into the hippocampus. Total α-syn antibody was used for these experiments. a Representative low and
(b) high magnification of LV-control injected ipsi-laterally in α-syn KO mice revealed complete absence of any α-syn immunoreactivity in the
hippocampus. c Representative low magnification and (d) high magnification of α-syn immunoreactivity in the ipsi-lateral and contra-lateral
sides following LV-control injection in non-tg mice. e Representative low and (f) high magnification of α-syn immunoreactivity in the ipsi-lateral and
contra-lateral sides following LV-control injection in α-syn tg mice. g Representative low magnification and (h) high magnification of α-syn
immunoreactivity in the ipsi-lateral and contra-lateral sides following unilateral LV-α-syn injection in α-syn KO mice. i Representative low magnification
and (j) high magnification of α-syn immunoreactivity in the ipsi-lateral and contra-lateral sides following LV-α-syn injection in non-tg mice.
k Representative low and (l) high magnification of α-syn immunoreactivity in the ipsi-lateral and contra-lateral sides following LV-α-syn
injection in α-syn tg mice. Low magnification scale bar = 250 μm; high magnification scale bar = 25 μm. N = 5 per group
Spencer et al. Acta Neuropathologica Communications  (2017) 5:7 Page 5 of 15
(Fig. 2g, h) and some of these structures appeared to be
associated with dystrophic neurites (Fig. 2g, h).
Non-tg mice (Fig. 2i, j) and α-syn tg mice (Fig. 2k, l)
showed similar distributions of α-syn-KO, but with rela-
tive higher levels of pathology likely related to the base-
line levels of α-syn expression. In both models, stronger
immunoreactivity was detected in the ipsilateral hippo-
campus, as expected from the protein overexpression,
including labeling of neurons and axons. In the contra-
lateral hippocampi α-syn immunostaining was found in
axons along the trans-hippocampal tracts (commissural
pathway) and in dystrophic neurites (Fig. 2i-l, left
panels). Since α-syn KO, non-tg, and α-syn tg mice
injected with the LV-control (empty vector) did not
show detectable increases in α-syn immunoreactivity in
the ipsilateral or contralateral sides when compared to
non-injected controls (Fig. 2a, f ), all ensuing experi-
ments focused on alterations in α-syn KO, non-tg, and
α-syn tg mice injected with LV-α-syn.
To further confirm the neuritic localization of α-syn in
the contralateral side of the α-syn KO mice, double
immunolabeling was performed with antibodies (Ab)
against α-syn and phosphorylated neurofilaments (p-NF,
SMI312 Ab; axonal marker). Image analysis by confocal
microscopy of the α-syn KO, non-tg, and α-syn tg mice
indicated that about 40% of the α-syn aggregates along
the hippocampus (Fig. 3a) and corpus callosum (Fig. 3b)
in the contra-lateral side co-localized with the SMI312
antibody, indicating their intra-axonal locality, while the
remainder surrounded the axons (Fig. 3b). To verify that
the α-syn signal detected in the contralateral side was
the results of the axonal transport and accumulation of
the protein and not due to migration of the injected
virus, PCR analysis for the viral human α-syn or GFP
DNA was performed. First, to confirm that α-syn protein
was migrating axonally rather than the virus, immuno-
fluorescence analysis was performed of brain sections
from mice injected with LV-α-syn. This study showed
that granular and pyramidal cells in the ipsilateral side
displayed strong α-syn immunostaining that extended to
the neuritic process (Fig. 4a). In the contralateral side α-
syn immunostaining was observed in the projecting zone
in the inner layer of the molecular layer of the dentate
(Fig. 4a). LV-α-syn DNA was only detected in the hippo-
campus of the side injected (ipsilateral) (Fig. 4b), but not
the contralateral side in all three genotypes tested
(Fig. 4b). In contrast, mice that received injection of LV-
GFP showed signal only in neurons cells in the ipsilat-
eral side, but little or no GFP signal was observed in
axons or the contra-lateral side (Fig. 4c). By PCR, the
GFP DNA was detected in the ipsilateral side but not in
the contralateral (Fig. 4d). For both, the α-syn and GFP
levels of DNA in the contra-lateral side were comparable
to background.
Passive immunotherapy reduces α-syn axonal accumulation
and transport to the contra-lateral side following unilateral
LV-α-syn injection
First, to confirm that the antibody trafficked into the
CNS, Alexa-tagged 27-1 or 1H7 were injected into the
tail vein and the brains analyzed 24 h after the injection.
While with the 27-1 control, little or no fluorescent sig-
nal was detected in the CNS, in α-syn KO, non-tg and
α-syn tg mice that received LV-α-syn injections, fluores-
cent Alexa signal was detected associated with neurons
in a granular fashion (Fig. 5). To assess the effects of im-
munotherapy in the axonal transport and accumulation,
groups of LV-α-syn-injected α-syn-KO, non-tg and α-
syn tg mice were immunized weekly with intraperitoneal
injections (30 mg/Kg) of either control IgG (27-1) or the
Fig. 3 Confocal image analysis of α-syn localization in the contralateral side in α-syn KO, non-tg, and α-syn tg mice. Brain sections were
immunolabeled with antibodies against CT-truncated α-syn and phosphorylated neurofilaments (p-NF; axonal marker). a Confocal image analysis of
α-syn (red) and p-NF(green) in the (a) hippocampus and (b) axonal tracts on the contralateral side in α-syn KO, non-tg, and α-syn tg mice. White
arrowhead indicates landmark for each image set. Scale bar = 10 μm. N = 5 per group
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1H7 antibody (Fig. 1c) for a total 13 weeks, starting
1 week post-LV injection (Fig. 1a). Both the 1H7 anti-
body and 21-1 control immunotherapies were well-
tolerated with all of the mice remaining healthy and with
similar weight gains across groups. The α-syn-KO mice
treated with 27-1 showed abundant expression and ac-
cumulation of α-syn in the hippocampus ipsilateral to
the injection while in the contralateral side, α-syn was
present in axons and in the molecular layer of the den-
tate gyrus (Fig. 6a, b). In contrast in animals treated with
the 1H7 antibody there was approximately a 45% reduc-
tion (P < 0.05) in α-syn both ipsi- and contra-lateral to
the site of injection (Fig. 6a, b), when compared to the
isotype control group.
Similarly, non-tg mice (Fig. 6c, d) and α-syn tg mice
(Fig. 6e, f ) treated with 27-1 showed increased expres-
sion and accumulation of α-syn in the hippocampus ipsi-
lateral and contralateral to the injection when compared
to non-injected mice. Both the non-tg and α-syn tg mice
treated with the 1H7 antibody showed a significant (p <
0.05) and robust reduction in α-syn axonal accumulation
and pathology in both the ipsilateral and contralateral
sides compared to IgG control (Fig. 6c, d).
More detailed analysis of the axons along the ipsi- and
contra-lateral sides showed accumulation of α-syn in the
axons and in dystrophic neurites in the 27-1 treated α-
syn KO (Fig. 7a), non-tg (Fig. 7b), and α-syn tg (Fig. 7c)
animals, while the 1H7-treated mice presented substan-
tially lower levels of axonal pathology in all three geno-
types (Fig. 7a-c).
Immunization with the 1H7 antibody reduces the α-syn
mediated degeneration of axons following unilateral
LV-α-syn injection
Next, we investigated the effects of the immunotherapy
on the axonal pathology. For this purpose, sections were
immunostained with the SMI312 antibody against phos-
phorylated neurofilaments and analyzed by confocal mi-
croscopy. Interestingly, both IgG treated α-syn-KO
(Fig. 8a, b) and non-tg mice (Fig. 8c, d) displayed a sig-
nificant (p < 0.05) reduction in axons immunostained
with the SMI312 antibody in the contralateral side, when
compared to the ipsilateral side, indicating that the
axonal dissemination of α-syn might promote a higher
degree of toxicity than the over-expression of that pro-
tein itself. When treated with 1H7 antibody, both α-syn
Fig. 4 Immunofluorescent and PCR analysis of LV-DNA in the hippocampus of α-syn KO, non-tg and α-syn tg mice. a Representative
immunofluorescent images with an anti-synuclein antibody (syn-211) at low and high magnification of the contra- and ipsi-lateral CA1
hippocampal regions following unilateral LV-α-syn injection. In the ipsilateral side α-syn was detected in nerve cell bodies and neurites
in the hippocampus, and in the contralateral side in the molecular layer of the dentate gyrus. b By PCR LV-α-syn was detected at high
levels in the ipsilateral side and at background levels in the contralateral side. c Representative fluorescent images at low and high
magnification of the contra- and ipsi-lateral CA1 hippocampal regions following unilateral LV-GFP injection. GFP was detected primarily in the neuronal
cell bodies in the ipsilateral but not in the contralateral side. d LV-GFP DNA was detectable above background levels in the ipsilateral but not
the contralateral side in all genotypes. For all experiments, PCR expression of LV DNA was normalized to GAPDH. *P <0.05 using a Student’s
t-test comparing contra- and ipsilateral sides within a genotype. N = 5 per group. Low magnification scale bar = 100 μm; high magnification
scale bar = 10 μm
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KO (8A, B) and non-tg (8C, D) mice displayed signifi-
cantly higher levels of intact SMI312 immunoreactive
axons (P < 0.05) when compared to IgG control. A sub-
stantially higher degree of axonal loss was observed in
α-syn tg mice in both ipsi- and contralateral sides of LV-
α-syn injection, when compared to the other genotypes
(Fig. 8e, f ). Strikingly, despite this higher level of axonal
pathology in α-syn tg mice, the immunization with 1H7
antibody significantly protected against the axonal loss
in this genotype (P < 0.05 compared to 27-1) and to
levels found in comparable other genotypes (Fig. 8b, d).
In order to further investigate the relationship between
the α-syn-associated axonal pathology and the effects of
immunotherapy, brain sections were double labeled with
antibodies against α-syn and the SMI312 antibody. Con-
sistent with the results discussed above, mice of all three
genotypes injected with LV-α-syn showed a higher de-
gree of colocalization between α-syn and SMI312 in dys-
trophic neurites in the contralateral side of IgG control
(27-1) versus 1H7-treated mice (Fig. 9a). Immunization
with 1H7 antibody resulted in a significant reduction
(p < 0.05) of 50%, 35% and 25% in α-syn/SMI312 immu-
noreactive dystrophic neurites in the contralateral side
in the α-syn-KO, non-tg and α-syn tg mice, respectively
(Fig. 9b, c). Taken together these results support the
notion that the 1H7 antibody reduced the axonal trans-
port and accumulation of α-syn and prevented the as-
sociated axonal pathology, irrespective of the baseline
levels of α-syn expression.
To determine if in the immunized mice, microglial
clearance plays a role in the removal of propagating α-
syn, double-labeling studies were performed in sections
of the α-syn KO, non-tg and α-syn tg mice injected with
LV-α-syn and treated with 27-1 (control) or 1H7 anti-
body (Fig. 10). In mice treated with 27-1, microglia
(FITC, green channel)) was detected in the proximity to
small granular aggregates of α-syn (Tyramide red, red
channel) but little (under 1%) (Fig. 10c). In contrast,
mice treated with 1H7 showed a higher proportion of
microglia containing granular deposits of α-syn (Fig. 10b
and c).
Effects of passive immunization with the 1H7 antibody in
the water maze task in a viral vector model of α-syn
mediated axonal pathology
In order to evaluate the effects of passive immunization
with the α-syn antibody on memory and learning in the
combined tg and lentivirus model, groups of α-syn-KO,
non-tg and α-syn tg mice that received unilateral intra-
hippocampal LV-α-syn injection were tested in the water
maze following the immunization period (13 weeks)
(Fig. 1a). During the initial training part of the test when
the platform was visible (cued; days 1-3), all groups per-
formed at comparable levels as determined by repeated
measures two-way ANOVA (Fig. 11a).
Following the cued platform session, the mice under-
went 4 days of testing during which the platform was
submerged and hidden from view (days 4-7). On the first
day of testing with the hidden platform the non-tg and
α-syn tg performed comparably, however the α-syn KO
mice displayed some deficits (Fig. 11a). Over the next
3 days of testing, the performance of both the 27-1- and
1H7-treated non-tg mice improved in terms of the dis-
tance of their swim path and the time taken to locate
the platform (Fig. 11a). In contrast, the performance of
the 27-1-treated α-syn tg mice did not improve to the
same extent (Fig. 9a) and a significant difference was ob-
served between the 27-1-treated α-syn tg mice and non-
tg mice. The α-syn tg mice immunized with the 1H7
took a significantly shorter time to locate the hidden
platform in comparison to 27-1-treated α-syn tg mice
(Fig. 11a) indicating that passive immunization with
those antibodies was able to ameliorate the memory and
learning deficits observed in the 27-1-treated α-syn tg
mice. In contrast, both the 27-1 and 1H7 treated α-syn
KO mice required more time to find the submerged
platform (Fig. 11a).
On day 8, the platform was removed and time
expended in the quadrant where the platform was
Fig. 5 Confocal analysis of systemic antibody trafficking to the CNS.
Representative images from α-Syn KO, non-tg, and α-syn tg mice
that were systemically injected (tail vein) with either Alexa-tagged
27-1 (control) or 1H7 antibodies and the brains were analyzed 24 h
later. N = 3. Scale bar = 15 μm
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located was analyzed (probe test). The α-syn KO mice
treated with 27-1 expended less time in the target quad-
rant while mice treated with 1H7 displayed a trend to-
ward more time in the target quadrant (Fig. 11b). For
the non-tg mice both the 27-1 and 1H7 treated mice
remained most of the recorded time in the target quad-
rant (Fig. 11b). Finally, the 27-1 treated α-syn tg mice
expended less time in the target quadrant while α-syn tg
treated with 1H7 expended more time comparable with
the non-tg mice (Fig. 11b).
Fig. 6 Immunohistochemical analysis of passively immunized mice following unilateral LV-α-syn injection. α-Syn KO, non-tg, and α-syn tg mice
were passively immunized weekly for 13 weeks with intraperitoneal injections of either 27-1 (control) or 1H7 (α-syn antibody) beginning one
week after LV-α-syn unilateral injection. Pathological analysis was conducted 16 weeks following unilateral LV-α-syn injection. Photomicrographs
are of low and high magnification, with the high magnification image identified by the boxed-inset in the low magnification images. For these
experiments an antibody against total α-syn was used. a Representative photomicrographs and (b) computer-aided analysis of contra- and ipsi-lateral
hippocampus immunostained with an antibody against α-syn from α-syn KO mice immunized with 27-1 (control; n = 8) or 1H7 (α-syn antibody; n = 9).
c Representative photomicrographs and (d) computer-aided analysis of contra- and ipsi-lateral hippocampus immunostained with an antibody against
α-syn from non-tg mice immunized with 27-1 (control; n = 8) or 1H7 (α-syn antibody; n = 9). e Representative photomicrographs and (f)
computer-aided analysis of contra- and ipsi-lateral hippocampus immunostained with an antibody against α-syn from α-syn tg mice immunized with
27-1 (control; n = 8) or 1H7 (α-syn antibody; n = 8). *P-value < 0.05 using ANOVA followed by Dunnett’s post-hoc test comparing 27-1 (control) and
1H7 (antibody) within a hemisphere, and #P-value < 0.05 using ANOVA followed by Tukey-Kramer post ho test comparing contra- and ipsilateral sides.
Low magnification scale bar = 100 μm. High magnification scale bar = 25 μm
Fig. 7 Effects of passive immunization on axonal accumulation of α-syn in ipsi- and contralateral sides. α-Syn KO, non-tg, and α-syn tg mice were
passively immunized (intraperitoneal injections) weekly for 13 weeks with either 27-1 (control) or 1H7 (α-syn antibody) beginning one week after
LV-α-syn unilateral injection. Pathological analysis was conducted 16 weeks following unilateral LV-α-syn injection. Representative photomicrographs of
total α-syn accumulation in hippocampal axons in (a) α-syn KO, (b) non-tg, and (c) α-syn tg mice. Arrows indicate dystrophic neurites. Scale bar = 25 μm
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Discussion
The present study developed a new mouse model of dis-
semination and accumulation of α-syn in axons on the
contralateral side by performing unilateral intra-cerebral
injections with a LV-α-syn vector construct in non-tg, α-
syn KO, and α-syn tg mice. We then used this model to
assess the effects of passive immunization with the anti-
α-syn antibody 1H7 on the axonal transport and accu-
mulation of α-syn in α-syn KO, non-tg and α-syn tg
mice that received unilateral intra-hippocampal injection
with a lentivirus expressing human α-syn. Previous
studies have shown that α-syn oligomers can be released
by affected neurons and transmit trans-axonally and
through other mechanisms such as release of free α-syn,
exoxomes or nanotubules to adjacent neurons and glial
cells leading to neurotoxicity and inflammatory re-
sponses [2, 3, 8, 10, 12, 31, 35], thus suggesting that
immunotherapy might prevent pathological responses
by neutralizing α-syn species and blocking transmis-
sion [72].
Using the approach of unilaterally injecting LV-α-syn
in the hippocampus, we were able to observe axonal
transport and accumulation of α-syn in the contra-
lateral hemisphere. One likely mechanism for the accu-
mulation of α-syn in the contra-lateral hemisphere is
trans-synaptic propagation [30] in which α-syn is trans-
mitted from the pre-synaptic neuron originating in the
ipsi-lateral hemisphere to post-synaptic neuron in the
contra-lateral hemisphere. Our results are consistent
with previous studies that injected pre-formed α-syn fi-
brils into the olfactory bulb [38], striatum [38] or adeno-
associated viral vector (AAV)-α-syn into the vagus nu-
cleus [71]. These models of α-syn propagation used wt
mice, which were injected unilaterally, and the α-syn
propagation was followed sequentially through various
connected brain regions, as well as in the contralateral
brain region [54]. While preformed α-syn fibrils have a
limiting half-life, viral vector models continuously ex-
pressing α-syn can overcome this limitation allowing for
the long-term study of α-syn [54]. Consistent with these
previous studies, the present study showed abnormal
patterns of α-syn accumulations along axons, often asso-
ciated with axonal dystrophy, as well as accumulation of
the protein in neuronal bodies of contralateral hippo-
campus. While the presence of α-syn in axons could be
explained by transport of α-syn along the commissural
fibers that interconnect both hippocampi, the presence
of intra-somatic α-syn pathology is suggestive of trans-
synaptic propagation, and expands upon these previous
models, which evaluated α-syn propagation from the
olfactory bulb [38] and brain stem [71], respectively.
Unlike previous papers using tg or viral vector to
study local immunization against α-syn, we demon-
strated the effects of an α-syn monoclonal antibody,
1H7, administered systemically using the LV-α-syn
model. Anti-α-syn immunizations have been previously
Fig. 8 Confocal analysis of phosphorylated neurofilaments in 1H7 passively immunized mice. α-Syn KO, non-tg, and α-syn tg mice were passively
immunized weekly for 13 weeks with either 27-1 (control) or 1H7 (α-syn antibody) beginning one week after LV-α-syn unilateral injection.
Pathological analysis of axonal density using SMI312 antibody against phosphorylated neurofilaments was conducted 16 weeks following
unilateral LV-α-syn injection. a Representative images and (b) computer-aided analysis of axonal density in the contra- and ipsilateral side of
α-syn KO mice. c Representative images and (d) computer-aided analysis of axonal density in the contra- and ipsilateral side of non-tg mice.
e Representative images and (f) computer-aided analysis of axonal density in the contra- and ipsilateral side of α-syn tg mice. *P-value < 0.05
using ANOVA followed by Dunnett’s post-hoc test comparing 27-1 (control) and 1H7 (antibody) within a hemisphere. #P < 0.05 using ANOVA
followed by Tukey-Kramer post hoc test comparing contra- and ipsilateral sides. Scale bar = 30 μm
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shown to be effective in AAV-α-syn propagation models
using N-terminal α-syn antibody by blocking α-syn ac-
cumulation [71]. 1H7 was previously demonstrated to
reduce the accumulation and propagation of CT-
truncated α-syn and improved axonal and motor deficits
via a mechanism that might involve protecting α-syn
from CT cleavage in the extracellular space in a trans-
genic α-syn mouse model [19].
Both in the current study and in previous study [19]
we showed that 1H7 was effective in vivo. While the
mechanism of action for how 1H7 immunization
blocked α-syn propagation has yet to be determined, it
is possible the antibody bound and neutralized extracel-
lular α-syn species, preventing their binding to neurons
and internalization into the cytoplasm [3]. Furthermore,
once opsonized by the 1H7 antibody, the α-syn aggre-
gates may be cleared by microglial phagocytosis [34],
which has also been suggested as the major scavenger of
extracellular α-syn. Supporting this hypothesis is our
current finding that microglia co-localized with α-syn,
which is indicative of extracelluar α-syn clearance by
microglia in a similar manner to what has been previ-
ously reported [34], It is also possible that the 1H7 anti-
body works by blocking binding to and uptake by
neurons, halting templating and neuron-to-neuron
propagation [66]. An alternate mechanism for 1H7 in-
cludes the possible inhibition of α-syn aggregation. Since
1H7 binds to an epitope proximal to the non-amyloid β
component (NAC) region of a-syn, the antibody might
potentially mask hydrophobic pockets and modify α-syn
folding states that are required for self aggregation.
We also show that immunotherapy in our model of
α-syn axonal transport and accumulation improved
axonal pathology. Dickson et al. has previously de-
scribed extensive hippocampal pathology in Lewy body
disease [15]. In our LV-α-syn models we recapitulated
the hippocampal pathology and then applied immuno-
therapy to mitigate the axonal pathology and improved
synaptic trafficking and axonal transport, although it is
possible that the antibody has additional mechanisms
further downstream which partially contribute to re-
duced α-syn.
Fig. 9 Co-localization of neurofilament marker SMI312 and CT-α-syn was reduced in passively immunized α-syn tg mice. To analyze if passive
immunization altered the subcellular distribution of CT-α-syn, double labeling of brain sections of α-syn KO, non-tg, and α-syn tg mice that were passively
immunized weekly for 13 weeks with either 27-1 (control) or 1H7 (α-syn antibody) beginning one week after LV-α-syn unilateral injection were analyzed
using SMI312 antibody against phosphorylated neurofilaments (p-NF) and the CT-α-syn antibody SYN105 was conducted 14 weeks following unilateral LV-
α-syn injection. a Representative confocal images of the contralateral neuropil in brain sections from α-syn KO, non-tg, and α-syn tg mice immunized with
27-1 (control), or (b) immunized with 1H7 (antibody). Arrows indicate co-localization of the SMI312 signal with CT-α-syn in neurofilament-like structures.
c Analysis of the percentage of co-localization between the neurofilament marker SMI312 and the CT-α-syn antibody SYN105. Error bars represent ± SEM.
*P <0.05 when statistically analyzed using a Student’s t-test. Scale bar = 25 μm. α-Syn KO mice + 27-1 (control) n= 8; α-syn KO+ 1H7 antibody n= 9; non-tg
mice + 27-1 (control) n= 10; non-tg mice + 1H7 antibody n= 9; α-syn tg mice + 27-1 (control) n= 8; α-syn tg mice + 1H7 antibody n= 8
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Fig. 11 Passive immunization with CT-α-syn antibodies improved behavioral deficits in α-syn KO and α-syn tg mice. The effect of immunization with CT-α
syn antibodies on learning as well as memory and motor performance were analyzed by water maze. a Performance in the water maze (distance to the
platform) during the cued with submerged platform tests in mice immunized with 27-1 (control), or with 1H7 (antibody). b Probe test
performance, measured as the time spent in correct quadrant by mice passively immunized with either 27-1 or 1H7 antibodies. Error bars represent
± SEM. *P < 0.05 when comparing 27-1-immunized mice to 1H7-immunized mice within genotype. α-Syn KO mice + 27-1 (control) n = 8; α-syn KO +
1H7 antibody n = 9; non-tg mice + 27-1 (control) n = 10; non-tg mice + 1H7 antibody n = 9; α-syn tg mice + 27-1 (control) n = 8; α-syn tg mice + 1H7
antibody n = 8
Fig. 10 Co-localization of microglial marker Iba-1 and α-syn was increased in passively immunized α-syn tg mice. To analyze if passive
immunization was associated with microglial clearance of α-syn, double labeling of brain sections of α-syn KO, non-tg, and α-syn tg mice that
were passively immunized weekly for 13 weeks with either 27-1 (control) or 1H7 (α-syn antibody) beginning one week after LV-α-syn unilateral
injection were analyzed using Iba-1 antibody against microglia and α-syn (syn-211)-positive aggregates was conducted 14 weeks following
unilateral LV-α-syn injection. Double labeled sections were analyzed with the laser scanning confocal microscope. Panels in red represents
α-syn (syn-211 antibody), and green represents Iba-1(a) Representative confocal images of the contralateral hippocampal neuropil in brain sections
from α-syn KO, non-tg, and α-syn tg mice immunized with 27-1 (control), or (b) immunized with 1H7 (antibody). Arrows indicate co-localization of the
Iba-1 signal with α-syn in microglia. c Analysis of the percentage of co-localization between the microglial marker Iba-1 and the α-syn syn-211
antibody. Error bars represent ± SEM. α-Syn KO mice + 27-1 (control) n = 8; α-syn KO + 1H7 antibody n = 9; non-tg mice + 27-1 (control) n = 10;
non-tg mice + 1H7 antibody n = 9; α-syn tg mice + 27-1 (control) n = 8; α-syn tg mice + 1H7 antibody n = 8. Scale bar = 10 μm
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Conclusions
Here we developed a new model of α-syn transmission
in mice to test the effects of anti-α-syn antibodies at
decreasing synuclein trans-axonal dissemination and re-
lated deficits. We show that a new antibody, denomi-
nated 1H7, that recognizes α-syn 91-99 aa residues was
effective at mitigating the axonal pathology and im-
proved synaptic trafficking and axonal transport, al-
though it is possible that the antibody has additional
mechanisms further downstream which partially contrib-
ute to reduced α-syn. Together this study supports the
notion that passive immunotherapy with antibodies tar-
geting specific domains of α-syn are capable of reducing
axonal transport and accumulation of α-syn from ipsi-
lateral to contra-lateral hemispheres and provides a
novel mechanism trough which immunotherpay might
be of potential interest to the treatment of PD, DLB and
related synucleinopathies.
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